<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Eikon Therapeutics, Inc. Common Stock — News on 6ix</title>
    <link>https://6ix.com/company/eikon-therapeutics-inc-common-stock</link>
    <description>Latest news and press releases for Eikon Therapeutics, Inc. Common Stock on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 30 Mar 2026 11:48:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/eikon-therapeutics-inc-common-stock" rel="self" type="application/rss+xml" />
    <item>
      <title>Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates</title>
      <link>https://6ix.com/company/eikon-therapeutics-inc-common-stock/news/eikon-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-clinical-and-corporate-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/eikon-therapeutics-inc-common-stock/news/eikon-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-clinical-and-corporate-updates</guid>
      <pubDate>Mon, 30 Mar 2026 11:48:00 GMT</pubDate>
      <description>Closed upsized initial public offering in February 2026, raising $381 million in gross proceedsCompleted enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 non-small cell lung cancer MILLBRAE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced fourth quarter and full</description>
    </item>
    <item>
      <title>Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering</title>
      <link>https://6ix.com/company/eikon-therapeutics-inc-common-stock/news/eikon-therapeutics-announces-pricing-of-upsized-initial-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/eikon-therapeutics-inc-common-stock/news/eikon-therapeutics-announces-pricing-of-upsized-initial-public-offering</guid>
      <pubDate>Thu, 05 Feb 2026 00:59:00 GMT</pubDate>
      <description>MILLBRAE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing important, innovative medicines to address serious unmet medical needs, today announced the pricing of its upsized initial public offering of 21,177,600 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Eikon has granted the underwriters a 30-day option to purchase up to an additional 3,176,6</description>
    </item>
  </channel>
</rss>